Clearwater Analytics Completes HSR Waiting Period for Enfusion Deal

Clearwater Analytics (CWAN) and Enfusion (ENFN) have announced the expiration of the waiting period necessary for their acquisition. This acquisition is set to finalize in Q2 2025, pending closing conditions. Investors should monitor stock reactions closely.

Date: 27-02-2025

AI Rating: 7

Overview of Acquisition: Clearwater Analytics Holdings Inc. (CWAN) has confirmed the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act concerning its acquisition of Enfusion Inc. (ENFN). This is a critical step as it fulfills one of the necessary conditions to complete the transaction.

The acquisition is projected to close in the second quarter of 2025, contingent on the fulfillment or waiver of customary conditions including shareholder approval from Enfusion.

Transaction Details: The agreed purchase price is $11.25 per share for Enfusion, which will be composed of $5.85 per share in cash and $5.40 per share in Clearwater Class A stock. This deal structure indicates a significant commitment by Clearwater Analytics towards enhancing its portfolio by incorporating Enfusion, which could potentially boost its market position post-acquisition. However, details regarding earnings per share (EPS), revenue growth, or other financial metrics related to this acquisition are not provided in the text.

As an investor, the timeline for completion and the conditions attached to the deal are important. The April 24, 2025, deadline for completion could have implications for both companies' stock prices, influencing market sentiment based on perceived synergies of the merger and the overall health of both firms leading up to the anticipated closing.

Stocks: CWAN ENFN